Benzinga | Aug 10, 2020 08:15AM EDT

UroGen Pharma Q2 EPS $(1.44) Beats $(1.58) Estimate, Sales $372.00K Beat $260.00K Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.58) by 8.86 percent. This is a 33.33 percent decrease over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $372.00 thousand which beat the analyst consensus estimate of $260.00 thousand by 43.08 percent. This is a 1.97K percent increase over sales of $18.00 thousand the same period last year.